Sinovac completes Phase I trial of high-dose flu vaccine in adults 60 and older
Registry record for Sinovac's high-dose split-virion influenza vaccine trial was posted, showing the study already completed with 50 participants enrolled.
Sinovac Biotech had one influenza vaccine item posted to the registry this week.
- Sinovac Biotech Co., Ltd sponsored a randomized, double-blind, active-controlled Phase I trial evaluating the safety and immunogenicity of its high-dose, split-virion inactivated influenza vaccine in adults aged 60 and older.1 The study is listed as completed, with a start date of 2025-08-21 and study completion on 2026-02-24, and was first posted to the registry on 2026-07-30. Fifty participants were enrolled and randomly assigned 1:1 to receive either the investigational high-dose vaccine or the active control vaccine, Anflu.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.